background
previous
identifi
two
hydrolyz
tannin
chebulag
acid
chla
punicalagin
pug
block
herp
simplex
viru
type
entri
spread
compound
inhibit
viral
glycoprotein
interact
cell
surfac
glycosaminoglycan
gag
base
properti
evalu
antivir
efficaci
sever
differ
virus
known
employ
gag
host
cell
entri
result
extens
analysi
tannin
mechan
action
perform
panel
virus
attach
entri
step
infect
virusspecif
bind
assay
analysi
viral
spread
treatment
compound
also
conduct
chla
pug
effect
abrog
infect
human
cytomegaloviru
hcmv
hepat
c
viru
hcv
dengu
viru
denv
measl
viru
mv
respiratori
syncyti
viru
rsv
concentr
dosedepend
manner
without
signific
cytotox
moreov
natur
compound
inhibit
viral
attach
penetr
spread
differ
degre
viru
specif
tannin
block
step
infect
hcmv
hcv
mv
littl
effect
postfus
spread
denv
rsv
could
suggest
intrigu
differ
role
gaginteract
virus
conclus
chla
pug
may
valu
broadspectrum
antivir
limit
emergingrecur
virus
known
engag
host
cell
gag
entri
studi
test
efficaci
tannin
vivo
certain
virus
justifi
viral
infect
respons
caus
signific
number
human
diseas
epidem
outbreak
morbid
mortal
vaccin
effort
proven
success
prevent
erad
viral
infect
mani
virus
target
immun
includ
dengu
viru
denv
human
cytomegaloviru
hcmv
hepat
c
viru
hcv
human
immunodefici
viru
hiv
respiratori
syncyti
viru
rsv
altern
mean
control
includ
use
antivir
drug
howev
current
licens
efficaci
drug
avail
prophylact
therapeut
antivir
treatment
global
public
health
therefor
constant
threat
emerg
reemerg
viral
infect
particularli
current
effect
vaccin
potenti
develop
drugresist
mutat
furthermor
due
increas
global
travel
trade
rapid
urban
increas
number
viral
pathogen
introduc
reintroduc
area
normal
indigen
reflect
recent
emerg
viral
outbreak
caus
sever
acut
respiratori
syndrom
sar
viru
influenza
viru
denv
west
nile
viru
wnv
measl
viru
mv
addit
potenti
outbreak
due
intent
accident
releas
viru
also
rais
seriou
concern
thu
effort
develop
antivir
therapi
requir
safeguard
public
viral
pathogen
antivir
therapi
target
defin
step
viral
life
cycl
specif
particular
viral
protein
exampl
includ
nucleosid
analogu
inhibit
herp
simplex
viru
hsv
replic
proteas
inhibitor
direct
hcv
proteas
neuraminidas
inhibitor
block
releas
influenza
viru
particl
infect
cell
howev
use
antivir
inevit
associ
potenti
risk
select
drugresist
virus
pose
signific
problem
clinic
manag
viral
infect
combin
cocktail
sever
inhibitor
often
necessari
reduc
risk
gener
drug
resist
mutant
best
exemplifi
highli
activ
antiretrovir
therapi
haart
treat
hiv
infect
howev
experi
combin
therapi
still
limit
potenti
produc
viral
escap
mutant
rule
altern
albeit
less
specif
antivir
therapi
interferon
ifn
howev
effect
limit
number
viral
pathogen
moreov
ifn
treatment
prohibit
expens
burden
advers
sideeffect
therapi
often
result
low
patient
complianc
characterist
make
ifn
impract
widespread
use
clinic
set
view
shortcom
clearli
need
develop
novel
costeffect
antivir
therapeut
particularli
harbor
broadspectrum
bioactiv
employ
control
limit
spread
viral
infect
immun
standard
therapi
unavail
glycosaminoglycan
gag
neg
charg
linear
polysaccharid
typic
sulfat
includ
chondroitin
sulfat
cs
heparan
sulfat
hs
repres
repertoir
complex
natur
glycan
local
within
extracellular
matric
cell
surfac
exhibit
heterogen
structur
allow
bind
wide
rang
protein
partner
adhes
molecul
chemokin
cytokin
growth
factor
matrix
protein
thu
gag
play
import
role
mani
biolog
process
profound
physiolog
consequ
includ
cell
signal
inflamm
angiogenesi
coagul
mani
virus
employ
gag
primari
entri
factor
facilit
infect
host
cell
includ
denv
hcmv
hcv
hiv
hsv
mv
rsv
other
interact
viral
glycoprotein
gag
usual
thought
increas
frequenc
initi
attach
viral
particl
target
cell
surfac
turn
enabl
subsequ
higher
affin
bind
virusspecif
entri
receptor
promot
viru
entri
import
gag
facilit
viral
infect
demonstr
use
solubl
heparin
gagdefici
cell
line
block
entri
sever
virus
previou
studi
identifi
chebulag
acid
chla
punicalagin
pug
figur
two
hydrolyz
tannin
isol
terminalia
chebula
retz
chebula
inhibitor
hsv
type
entri
spread
demonstr
two
structurallyrel
compound
mediat
antivir
activ
target
viral
glycoprotein
interact
cell
surfac
gag
take
note
fact
mani
virus
employ
gag
initi
bind
host
cell
base
evid
chla
pug
may
act
gagcompetitor
explor
antiviralpotenti
two
tannin
number
virus
known
interact
gag
viral
model
includ
denv
hcmv
hcv
mv
rsv
tabl
mani
diseas
associ
virus
lack
prevent
vaccin
andor
drug
treatment
option
inde
chla
pug
effici
inhibit
entri
spread
virus
vari
degre
suggest
chla
pug
potenti
novel
costeffect
broadspectrum
antivir
control
emergingrecur
infect
virus
engag
host
cell
surfac
gag
dulbecco
modifi
eagl
medium
dmem
alpha
minim
essenti
medium
amem
purchas
gibcoinvitrogen
carlsbad
ca
usa
fetal
bovin
serum
fb
penicillin
g
streptomycin
amphotericin
b
purchas
chemicon
billerica
usa
heparin
dimethylsulfoxid
dmso
vitro
toxicolog
assay
kit
xtt
base
purchas
sigma
st
loui
mo
usa
vero
african
green
monkey
kidney
cell
atcc
hel
human
embryon
lung
fibroblast
atcc
ccl
human
lung
carcinoma
atcc
cell
obtain
american
type
cultur
collect
atcc
rockvil
md
usa
cultur
dmem
supplement
fb
uml
penicillin
g
streptomycin
amphotericin
b
human
hepatocarcinoma
cell
deriv
provid
dr
charl
rice
rockefel
univers
new
york
ny
usa
human
epitheli
cell
deriv
larynx
carcinoma
provid
r
anderson
cell
cultur
medium
condit
describ
choslam
chines
hamster
ovari
cell
express
human
signal
lymphocyt
activ
molecul
receptor
wildtyp
measl
gener
previous
report
cultur
amem
supplement
fb
hcmv
strain
provid
dr
karen
l
mossman
mcmaster
univers
hamilton
canada
wildtyp
human
adenoviru
vsvgfp
vesicular
stomat
viru
green
fluoresc
protein
tag
describ
elsewher
viral
titer
antivir
assay
determin
standard
plaqu
assay
use
methanol
fixat
follow
crystal
violet
sigma
cellcultur
deriv
hcv
particl
produc
electropor
cell
use
construct
genotyp
kindli
provid
dr
charl
rice
harbor
gaussia
luciferas
report
allow
detect
viru
infect
previous
describ
hcv
viral
titer
antivir
assay
determin
immunofluoresc
stain
tcid
use
antibodi
gift
dr
charl
rice
luciferas
assay
dengu
viru
type
strain
rsv
serogroup
long
strain
atcc
propag
vero
cell
respect
viral
titer
antivir
assay
rsv
determin
immunohistochem
stain
plaqu
assay
use
antiflaviviru
group
antibodi
millipor
billerica
usa
antirsv
fusion
protein
antibodi
millipor
goat
antimous
igg
h
l
alkalin
phosphatas
ap
conjug
invitrogen
rsv
follow
develop
vector
black
ap
substrat
kit
vector
laboratori
burlingam
c
usa
base
previous
report
method
mvegfp
recombin
ichinoseb
wildtyp
measl
viru
isol
express
enhanc
green
fluoresc
protein
origin
obtain
dr
roberto
cattaneo
mayo
clinic
rochest
mn
usa
propag
marmoset
b
lymphoblastoid
cell
viral
titer
antivir
assay
determin
tcid
choslam
cell
basal
medium
contain
fb
antibiot
use
viru
infect
experi
viru
concentr
express
plaqu
form
unit
pfu
per
well
multipl
infect
moi
chla
pug
figur
isol
purifi
previous
describ
structur
confirm
highperform
liquid
chromatograph
method
coupl
uv
detect
electrospray
ioniz
mass
spectrometri
hplcuvesim
puriti
check
hplc
photodiod
array
detect
hplcpda
compound
dissolv
dmso
final
concentr
dmso
equal
toor
experi
heparin
serv
control
dissolv
steril
doubledistil
water
assay
unless
otherwis
specifi
test
compound
concentr
use
follow
base
antivir
dose
respons
deter
cell
per
well
plate
treat
test
compound
day
treatment
effect
cell
viabil
cytotox
concentr
cc
valu
test
compound
determin
base
xtt
carbonyl
hydroxid
assay
previous
report
respect
cell
line
rel
viral
dose
use
well
incub
period
test
compound
treatment
viral
cytopath
effect
take
place
indic
tabl
figur
specif
viru
assess
antivir
activ
tannin
panel
virus
hel
cellswel
vero
cellswel
cellswel
adenovirida
dsdna
cellswel
cell
seed
plate
cotreat
respect
viral
inoculum
figur
increas
concentr
test
compound
h
inoculum
drug
mixtur
remov
well
subsequ
wash
pb
twice
overlaid
fb
medium
contain
either
methylcellulos
sigma
hcmv
rsv
vsv
seaplaqu
agaros
lonza
basel
switzerland
incub
h
day
depend
specif
viru
well
contain
hcmv
vsv
infect
analyz
standard
plaqu
assay
well
contain
rsv
infect
analyz
immunohistochem
stain
describ
viral
infect
effect
concentr
ec
test
compound
differ
viral
infect
calcul
previous
describ
evalu
antivir
activ
tannin
mvegfp
infect
choslam
cell
cell
well
seed
plate
viral
inoculum
increas
concentr
test
compound
coad
onto
cell
monolay
h
inoculum
drug
mixtur
remov
well
wash
pb
twice
overlay
amem
contain
fb
incub
h
plate
scan
typhoon
variabl
mode
imag
amersham
bioscienc
baie
durf
quebec
canada
egfp
express
analyz
imagequ
tl
softwar
amersham
bioscienc
viral
inhibit
ec
compound
base
viral
egfp
express
determin
previous
report
analyz
antivir
activ
tannin
hcv
infect
cell
cellswel
seed
plate
cell
monolay
cochalleng
viral
inoculum
increas
concentr
test
compound
h
inoculum
drug
mixtur
remov
well
follow
wash
pb
twice
overlay
dmem
contain
fb
incub
h
supernat
collect
assay
luciferas
activ
use
gaussia
luciferas
assay
kit
new
england
biolab
picker
canada
luminomet
promega
madison
wi
usa
hcv
infect
express
log
rel
light
unit
rlu
determin
viral
inhibit
ec
drug
hcv
infect
calcul
use
graphpad
prism
softwar
san
diego
ca
usa
valu
plot
dmso
control
treatment
viru
infect
viral
inactiv
assay
perform
previous
describ
incub
period
viral
dose
use
list
figur
differ
virus
mix
test
compound
incub
figur
longterm
drugviru
mixtur
subsequ
dilut
fold
subtherapeut
ineffect
concentr
low
serum
medium
inocul
respect
host
cell
seed
multiwel
plate
dilut
subtherapeut
concentr
prevent
effect
interact
drug
host
cell
surfac
comparison
virus
also
mix
test
compound
immedi
dilut
incub
period
subtherapeut
concentr
prior
infect
figur
shortterm
follow
incub
viral
absorpt
dilut
inocula
remov
well
wash
pb
twice
appli
overlay
medium
plate
incub
subject
assess
plaqu
assay
egfp
express
analysi
luciferas
assay
describ
analys
drug
effect
viral
attach
perform
base
host
cell
infect
method
virusspecif
cellular
enzymelink
immunosorb
assay
elisa
method
previous
describ
experi
carri
allow
viru
bind
preclud
entri
occur
effici
method
figur
differ
cell
type
prechil
h
cotreat
dose
respect
virus
test
compound
indic
time
inocula
drug
remov
cell
monolay
wash
icecold
pb
twice
appli
overlay
medium
incub
plaqu
assay
egfp
express
analysi
luciferas
assay
perform
describ
assess
host
cell
infect
method
figur
differ
cell
type
cellswel
seed
plate
grown
overnight
cell
monolay
prechil
h
cotreat
respect
virus
hcmv
moi
hcv
moi
moi
mv
moi
rsv
moi
variou
concentr
test
compound
addit
h
follow
viru
bind
period
inocula
drug
remov
cell
monolay
wash
icecold
pb
fixat
prechil
paraformaldehyd
pfa
pb
h
ice
point
well
block
bovin
serum
albumin
bsa
overnight
prevent
nonspecif
bind
bound
virus
cellular
surfac
detect
elisa
assay
wherebi
well
incub
follow
respect
mous
monoclon
primari
antibodi
dilut
pb
contain
bsa
h
wash
pbst
tween
pb
three
time
antihcmv
gb
antibodi
thermo
pierc
rockford
il
usa
antihcv
antibodi
austral
biolog
san
ramon
ca
usa
antiflaviviru
group
antibodi
antimeasl
hemagglutinin
antibodi
millipor
antirsv
fusion
protein
antibodi
sampl
subject
incub
h
goat
antimous
igg
conjug
horseradish
peroxidas
hrp
invitrogen
dilut
viral
penetr
assay
perform
previous
report
incub
period
viral
dose
use
indic
figur
monolay
differ
cell
type
prechil
h
infect
indic
time
respect
virus
allow
viru
bind
entri
inocula
remov
well
wash
icecold
pb
twice
treat
test
compound
indic
time
shift
facilit
viral
penetr
therefor
allow
assess
drug
effect
viral
intern
drug
afterward
remov
nonintern
extracellular
virus
detach
either
citrat
buffer
mm
sodium
citrat
mm
kcl
ph
pb
wash
well
wash
pb
twice
prior
cover
cell
monolay
overlay
medium
addit
incub
plaqu
assay
egfp
express
analysi
luciferas
assay
perform
describ
examin
drug
effect
post
viral
entri
cell
monolay
infect
respect
virus
viral
dose
incub
time
specifi
figur
follow
absorpt
period
inocula
remov
extracellular
virus
detach
citrat
buffer
pb
wash
describ
treat
test
compound
mix
overlay
medium
indic
time
plaqu
assay
egfp
express
assess
luciferas
assay
perform
describ
analysi
hcmv
infect
titer
standard
plaqu
assay
newli
seed
hel
cell
alpha
interferon
human
leukocyt
uml
sigma
includ
control
hcv
viral
celltocel
spread
assay
perform
previous
describ
modif
viral
dose
incub
period
indic
figur
briefli
differ
cell
type
infect
respect
virus
extracellular
virus
remov
citrat
buffer
pb
wash
specifi
earlier
well
cover
overlay
medium
contain
either
methylcellulos
rsv
seaplaqu
agaros
lonza
mv
case
hcmv
neutral
gamunex
antibodi
purifi
clinic
human
igg
provid
dr
andrew
c
issekutz
dalhousi
univers
halifax
ns
canada
overlay
medium
help
limit
viral
secondari
infect
thu
allow
monitor
celltocel
spread
viru
presenc
absenc
drug
plate
incub
initi
plaqu
format
test
compound
ad
overlay
medium
monitor
subsequ
incub
analysi
viral
plaqu
size
immunofluoresc
assay
fusion
inhibitori
peptid
fip
zdphelpheglyoh
sigma
also
serv
control
mv
examin
hcv
spread
base
previous
describ
protocol
modif
cell
electropor
hcv
rna
describ
establish
random
product
infect
cell
popul
mix
cell
ratio
seed
plate
assembl
hcv
particl
within
h
posttransfect
would
transmit
neighbor
cell
harbor
viral
rna
viral
spread
form
local
foci
ensu
incub
period
medium
chang
h
postelectropor
overlay
medium
contain
test
drug
control
methylcellulos
plate
incub
day
analysi
hcvposit
foci
immunostain
cell
line
provid
dr
rodney
russel
memori
univers
newfoundland
st
john
nl
canada
deriv
defici
hcv
receptor
allow
celltocel
transmiss
hcv
infect
includ
control
immunofluoresc
analysi
viral
plaqu
size
due
spread
overlay
media
remov
well
fix
icecold
methanol
block
bsa
sampl
treat
h
respect
mous
monoclon
primari
antibodi
dilut
pb
contain
bsa
antihcmv
gb
antibodi
antibodi
hcv
antiflaviviru
group
antibodi
antirsv
fusion
protein
antibodi
incub
well
wash
pb
three
time
appli
alexa
fluor
goat
antimous
igg
h
l
antibodi
invitrogen
dilut
hcmv
rsv
hcv
pb
contain
bsa
follow
incub
h
sampl
wash
pb
three
time
prior
visual
fluoresc
microscopi
fluoresc
express
mvegfp
could
readili
detect
without
addit
antibodi
photomicrograph
taken
magnif
leica
microsystem
wetzlar
germani
viral
plaqu
size
analyz
metamorph
softwar
molecular
devic
sunnyval
ca
usa
case
hcv
cellular
nuclei
stain
hoechst
dye
sigma
prior
visual
number
cell
virusposit
foci
determin
viru
test
total
five
random
virusposit
plaqu
evalu
treatment
group
per
independ
experi
comparison
made
viral
plaqu
stain
prior
drug
addit
endpoint
experi
data
plot
fold
chang
plaqu
area
broadspectrum
antivir
effect
chla
pug
chla
pug
evalu
antivir
effect
panel
envelop
virus
whose
entri
involv
cellular
surfac
gag
tabl
vesicular
stomat
viru
vsv
adenoviru
type
includ
comparison
indic
cytotox
cc
effect
antivir
concentr
ec
well
select
index
si
cc
ec
determin
viru
infect
host
cell
system
list
tabl
shown
figur
chla
pug
display
broadspectrum
antivir
effect
dosedepend
manner
compound
exhibit
signific
inhibitori
effect
envelop
virus
known
engag
gag
infect
includ
hcmv
hcv
mv
rsv
ec
si
tabl
tannin
especi
effect
rsv
ec
valu
two
compound
howev
display
limit
efficaci
si
infect
vsv
consist
fact
virus
previous
shown
requir
gag
entri
vsv
infect
gagdefici
cell
wherea
hsmediat
entri
import
absenc
primari
receptor
car
coxsackieviru
adenoviru
receptor
inhibit
maximum
solubl
heparin
remaind
studi
focus
effect
tannin
hcmv
hcv
mv
rsv
chla
pug
previous
observ
inactiv
particl
prevent
interact
host
cell
surfac
examin
whether
tannin
could
also
inactiv
differ
envelop
virus
prevent
subsequ
infect
natur
product
preincub
virus
dilut
subtherapeut
concentr
prior
infect
respect
host
cell
result
indic
chla
pug
abl
interact
hcmv
hcv
mv
rsv
virion
effect
irrevers
abrog
subsequ
infect
figur
block
paramyxovirus
mv
rsv
observ
wherea
near
inhibit
achiev
hcmv
hcv
data
suggest
chla
pug
directli
inactiv
free
viru
particl
neutral
infect
character
antivir
mechan
involv
explor
effect
chla
pug
hcmv
hcv
mv
rsv
attach
host
cell
surfac
upon
subsequ
membran
fusion
temperatur
chang
permit
viru
bind
entri
facilit
viru
entri
penetr
allow
examin
drug
effect
specif
event
tannin
compound
effect
prevent
attach
investig
virus
shown
readout
inhibit
infect
method
figur
elisabas
bind
assay
use
virusspecif
antibodi
detect
bound
viru
cell
monolay
method
figur
inhibit
viru
attach
chla
pug
similar
hcmv
hcv
rsv
rang
figur
mv
pug
appear
effect
chla
inhibit
entri
vari
compound
abil
abolish
bind
virus
confirm
decreas
virion
detect
cell
surfac
occur
dosedepend
manner
increas
concentr
tannin
figur
see
whether
chla
pug
retain
activ
viru
penetr
phase
test
virus
allow
bind
cell
surfac
allow
penetr
target
cell
membran
temperatur
shift
presenc
absenc
tannin
chla
pug
observ
impair
viru
entri
virus
result
protect
host
cell
infect
viru
examin
figur
heparin
exhibit
similar
inhibitori
effect
tannin
attach
test
virus
less
potent
inhibit
cell
penetr
hcmv
hcv
mv
inhibit
averag
therefor
chla
pug
abl
abrog
host
cell
bind
penetr
hcmv
hcv
mv
rsv
cell
entri
process
next
determin
antivir
activ
two
hydrolyz
tannin
control
spread
establish
infect
target
cell
monolay
infect
respect
test
viru
incub
without
compound
shown
figur
chla
pug
effect
inhibit
hcmv
hcv
mv
infect
protect
ineffect
growth
rsv
valid
tannin
effect
viru
celltocel
transmiss
examin
effect
drug
viral
plaqu
size
chang
area
plaqu
measur
use
either
viral
immunofluoresc
egfptag
report
virus
neutral
antibodi
methylcellulos
agaros
includ
overlay
medium
prevent
secondari
infect
uninfect
cell
throughout
monolay
ensur
viral
spread
occur
via
intercellular
junction
neighbor
infect
virusfre
popul
data
indic
viral
plaqu
hcmv
hcv
mv
infect
restrict
chla
pug
near
initi
size
wherea
plaqu
due
rsv
infect
unaffect
expand
figur
addit
file
figur
addit
file
figur
addit
file
figur
addit
file
figur
addit
file
figur
result
agreement
data
obtain
follow
postentri
drug
treatment
figur
hcmv
hcv
mv
rsv
shown
sensit
tannin
antivir
effect
thu
appear
two
tannin
effect
limit
postinfect
spread
hcmv
hcv
mv
ineffici
prevent
celltocel
transmiss
rsv
heparin
hand
display
limit
effect
spread
virus
postentri
figur
window
antivir
activ
chla
pug
heparin
differ
stage
viral
entri
spread
summar
tabl
inhibit
virushost
cell
entri
effect
antivir
control
strategi
base
way
viru
infect
host
cell
interact
viral
glycoprotein
cellular
membran
molecul
countermeasur
process
develop
exampl
protect
antibodi
elicit
vaccin
bind
viral
particl
prevent
infect
anoth
strategi
consist
use
monoclon
antibodi
small
molecul
bind
host
cell
receptor
block
viru
interact
exampl
includ
antibodi
direct
hcv
receptor
claudin
anoth
antagonist
maraviroc
interact
hiv
coreceptor
anoth
hiv
inhibitor
call
enfuvirtid
block
membran
fusion
viru
entri
amantidin
block
influenza
ion
channel
activ
entri
viral
assembl
hand
nonspecif
approach
direct
viru
influenc
membran
fluiditi
lipid
bilay
intercal
membran
fusion
rigid
amphipath
fusion
inhibitor
rafi
neutral
surfac
charg
cation
amphipath
sterol
squalamin
effect
wide
rang
envelop
virus
similarli
recent
consid
gag
receptor
target
potenti
antivir
therapi
two
natur
molecul
hydrolyz
tannin
class
chla
pug
possess
gagcompet
properti
studi
compound
display
signific
vitro
antivir
activ
varieti
virus
suggest
block
interact
gag
feasibl
way
prevent
infect
virus
find
add
list
molecular
strategi
develop
prevent
limit
viral
infect
previous
show
chla
pug
exert
antivir
effect
bind
viral
glycoprotein
interact
cell
surfac
gag
current
studi
compound
demonstr
effect
infect
virus
includ
hcmv
hcv
mv
rsv
whose
entri
known
sensit
neutral
heparin
tabl
similar
tannin
hypothes
bind
viral
glycoprotein
virus
cell
surfac
infect
cell
block
viru
attach
entri
cell
cell
spread
two
tannin
may
target
one
step
infect
includ
attach
membran
fusion
celltocel
fusion
mani
viral
glycoprotein
multipl
role
includ
bind
host
cell
surfac
gag
interact
higher
affin
receptor
mediat
membran
fusion
sinc
chla
pug
could
block
spread
rsv
might
reflect
situat
inhibitor
interact
specif
site
viral
glycoprotein
involv
attach
membran
fusion
cell
spread
function
conform
chang
viral
glycoprotein
could
result
bind
tannin
interact
cellular
microenviron
may
vari
differ
virus
exampl
heparin
observ
rel
ineffect
postentri
spread
virus
examin
could
due
fact
molecular
size
heparin
limit
access
viral
glycoprotein
intercellular
junction
addit
tannin
display
differenti
efficaci
virus
examin
tabl
interest
chla
pug
appear
particularli
select
rsv
could
due
higher
affin
compound
rsv
glycoprotein
detail
structureact
relationship
sar
studi
coupl
analysi
individu
viral
glycoprotein
would
necessari
clarifi
issu
addit
use
genet
alter
viru
lack
certain
glycoprotein
exampl
deltag
rsv
delet
glycoprotein
g
could
help
clarifi
tannin
antivir
mechan
although
vaccin
repres
prefer
method
protect
virus
limit
use
individu
alreadi
infect
viru
vaccin
also
associ
problem
suppli
cost
develop
coverag
deploy
efficaci
newli
emerg
rapidli
mutat
virus
antivir
therapi
proven
success
treatment
mani
pathogen
viral
infect
yet
develop
approv
includ
sever
infecti
agent
investig
studi
clinic
valu
current
antivir
drug
also
frequent
compromis
develop
drug
resist
variant
caus
recurr
viral
infect
broadspectrum
antivir
may
offer
relief
treatment
infect
although
mani
virus
use
gag
initi
infect
therapi
exploit
interact
yet
develop
heparin
also
type
gag
known
block
interact
viral
glycoprotein
gag
cell
cultur
studi
howev
clinic
use
vivo
frequentlongterm
administr
due
side
effect
relat
anticoagul
activ
convers
chla
pug
structur
differ
heparin
also
target
gaginteract
properti
virus
possess
much
higher
potenc
vivo
toxicolog
metabol
studi
tannin
explor
show
minim
toxic
furthermor
two
compound
could
massproduc
chemic
synthesi
extract
chebula
widespread
throughout
southeast
asia
make
attract
costeffect
drug
candid
therefor
develop
broadspectrum
antivir
use
chla
pug
structur
lead
compound
could
use
could
help
control
virus
hcv
denv
mv
rsv
especi
epidem
area
resourcepoor
countri
activ
vaccin
commerci
program
unavail
potenti
applic
includ
formul
tannin
topic
cream
gel
aerosol
inhal
incorpor
compound
materi
wipe
surgic
mask
protect
glove
conclus
demonstr
chla
pug
abil
function
broadspectrum
antivir
vitro
effect
prevent
infect
virus
util
gagassist
entri
includ
hcmv
hcv
denv
mv
rsv
natur
molecul
could
serv
new
therapeut
agent
help
limit
infect
virus
vaccin
fdalicens
drug
yet
exist
futur
clinic
applic
studi
investig
efficaci
vivo
specif
virus
explor
addit
file
figur
examin
chla
pug
treatment
hcmv
celltocel
spread
hel
cell
monolay
inocul
infect
hcmv
h
wash
pb
remov
excess
surfac
bound
viru
cover
overlay
medium
prevent
secondari
infect
initi
viru
plaqu
allow
form
subsequ
infect
chla
pug
heparin
dmso
control
ad
overlay
medium
addit
incub
time
analysi
viral
plaqu
size
immun
fluoresc
microscopi
day
postinfect
describ
method
repres
viru
plaquesfoci
shown
three
independ
experi
perform
scale
bar
indic
addit
file
figur
examin
chla
pug
treatment
hcv
celltocel
spread
cell
electropor
fulllength
hcv
replicon
rna
cover
overlay
medium
prevent
secondari
infect
initi
viru
plaqu
allow
form
subsequ
infect
chla
pug
heparin
dmso
control
ad
overlay
medium
addit
incub
time
analysi
viral
plaqu
size
immun
fluoresc
microscopi
day
postelectropor
describ
method
repres
viru
plaquesfoci
shown
three
independ
experi
perform
scale
bar
indic
addit
file
figur
examin
chla
pug
treatment
celltocel
spread
vero
cell
inocul
infect
h
wash
citrat
buffer
remov
excess
surfac
bound
viru
cover
overlay
medium
prevent
secondari
infect
initi
viru
plaqu
allow
form
subsequ
infect
chla
pug
heparin
dmso
control
ad
overlay
medium
addit
incub
time
analysi
viral
plaqu
size
immun
fluoresc
microscopi
day
postinfect
describ
method
repres
viru
plaquesfoci
shown
three
independ
experi
perform
scale
bar
indic
addit
file
figur
examin
chla
pug
treatment
mvegfp
celltocel
spread
choslam
cell
inocul
infect
mvegfp
h
wash
citrat
buffer
remov
excess
surfac
bound
viru
cover
overlay
medium
prevent
secondari
infect
initi
viru
plaqu
allow
form
subsequ
infect
chla
pug
heparin
fip
dmso
control
ad
overlay
medium
addit
incub
time
analysi
viral
plaqu
size
egfp
fluoresc
microscopi
h
postinfect
describ
method
repres
viru
plaquesfoci
shown
three
independ
experi
perform
scale
bar
indic
addit
file
figur
examin
chla
pug
treatment
rsv
celltocel
spread
cell
inocul
infect
rsv
h
wash
citrat
buffer
remov
excess
surfac
bound
viru
cover
overlay
medium
prevent
secondari
infect
initi
viru
plaqu
allow
form
subsequ
infect
chla
pug
heparin
dmso
control
ad
overlay
medium
addit
incub
time
analysi
viral
plaqu
size
immun
fluoresc
microscopi
h
postinfect
describ
method
repres
viru
plaquesfoci
shown
three
independ
experi
perform
scale
bar
indic
